Abstract
The risk of melanoma in patients with psoriasis has not been well-characterized. Certain TNF inhibitors have been shown to confer an increased incidence of melanoma, although notably, certolizumab pegol has not. Certolizumab pegol may be a reasonable therapeutic option in at-risk patients with moderate-to severe psoriasis, and topical therapies or acitretin should be considered first-line therapies for mild-to-moderate disease.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Hannuksela-Svahn A, Pukkala E, Laara E, et al. Psoriasis, its treatment, and cancer in a cohort of finnish patients. J Invest Dermatol. 2000;114:587–90.
Brauchli YB, Jick SS, Miret M, et al. Psoriasis and risk of incident cancer: an inception cohort study with a nested case-control analysis. J Invest Dermatol. 2009;129:2604–12.
Fuxench C, et al. The risk of cancer in patients with psoriasis: a population-based cohort study in the health improvement network. JAMA Dermatol. 2016;152(3):282–90.
Chen YJ, Wu CY, Chen TJ, Shen JL, Chu SY, Wang CB, Chang YT. The risk of cancer in patients with psoriasis: a population-based cohort study in Taiwan. J Am Acad Dermatol. 2011;65(1):84–91.
Bhattacharya T, Nardone B, Rademaker A, Martini M, Amin A, Al-Mudaimeagh HM, Kiguradze T, Schneider D, West DP. Co-existence of psoriasis and melanoma in a large urban academic centre population: a cross-sectional retrospective study. J Eur Acad Dermatol Venereol. 2016;30:83–5.
Lee MS, Lin RY, Chang YT, et al. The risk of developing non-melanoma skin cancer, lymphoma and melanoma in patients with psoriasis in Tai- wan: a 10-year, population-based cohort study. Int J Dermatol. 2012;51:1454–60.
Megna M, Napolitano M, Balato N, et al. Psoriasis in melanoma patients: a prospective pilot study. G Ital Dermatol Venereol. 2017;152(2):109.
Kappelman MD, Farkas DK, Long MD, et al. Risk of cancer in patients with inflammatory bowel diseases: a nationwide population-based cohort study with 30 years of follow-up evaluation. Clin Gastroenterol Hepatol. 2014;12:265–73.e1.
Ellinghaus D, Ellinghaus E, Nair RP, et al. Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. Am J Hum Genet. 2012;90:636–47.
Wang CQ, Akalu YT, Suarez-Farinas M, et al. IL-17 and TNF synergistically modulate cytokine expression while suppressing melanogenesis: potential relevance to psoriasis. J Invest Dermatol. 2013;133:2741–52.
Baliwag J, Barnes DH, Johnston A. Cytokines in psoriasis. Cytokine. 2015;73(2):342–50.
Wang S, Zhou M, Lin F, et al. Interferon-c induces senescence in normal human melanocytes. PLoS One. 2014;9(3):e9323.
Nardone B, Hammel JA, Raisch DW, Weaver LL, Schneider D, West DP. Melanoma associated with TNF-alpha inhibitors: a Research on Adverse Drug events And Reports (RADAR) Project. Br J Dermatol. 2014;170(5):1170–2.
Papp KA, Griffiths CEM, Gordon K, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5-years of follow-up. Br J Dermatol. 2013;168:844–54.
da Silva FR, de Souza CLF, Steiner D. Amelanotic melanoma during the use of ustekinumab for severe psoriasis. J Am Acad Dermatol. 2017;76:AB38.
Ustekinumab. First report of malignant melanoma: case report. Reactions Weekly. 2012;1389:41.
Ehmann LM, Tillack-Schreiber C, Brand S, Wollenberg A. Malignant melanoma during ustekinumab therapy of Crohn’s disease. Inflamm Bowel Dis. 2012;18:E199–200.
Strober B, Leonardi C, Papp KA, et al. Short and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: etanercept comparisons and integrated data. J Am Acad Dermatol. 2017;76:432–440.e17.
Reddy SP, Martires K, Wu JJ. The risk of melanoma and hematologic cancers in patients with psoriasis. J Am Acad Dermatol. 2017;76:639–47.
Buchbinder R, Barber M, Heuzenroeder L, Wluka AE, Giles G, Hall S, Harkness A, Lewis D, Littlejohn G, Miller MH, Ryan PF, Jolley D. Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum. 2008;59(6):794–9.
Stern RS, Nichols KT, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study. N Engl J Med. 1997;336(15):1041–5.
Whitmore SE, Morison WL. Melanoma after PUVA therapy for psoriasis. N Engl J Med. 1997;337:502–3.
Hearn RM, Kerr AC, Rahim KF, Ferguson J, Dawe RS. Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy. Br J Dermatol. 2008;159:931–5.
Archier E, Devaux S, Castela E, et al. Carcinogenic risks of Psoralen UV-A therapy and Narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012;26:22–31.
Naldi L. Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: facts and controversies. Clin Dermatol. 2010;28:88–92.
Lee E, Koo J, Berger T. UVB phototherapy and skin cancer risk: a review of the literature. Int J Dermatol. 2005;44:355–60.
De Haes P, Garmyn M, Verstuyf A, et al. 1,25-Dihydroxyvitamin D3 and analogues protect primary human keratinocytes against UVB-induced DNA damage. J Photochem Photobiol B. 2005;78:141–8.
Hui RL, Lide W, Chan J, Schottinger J, Yoshinaga M, Millares M. Association between exposure to topical tacrolimus or pimecrolimus and cancers. Ann Pharmacother. 2009;43:1956–63.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Reynolds, K.A., Pithadia, D.J., Wu, J.J. (2019). 79-Year-Old Male with Psoriasis and a History of Melanoma In Situ. In: Wu, J. (eds) Clinical Cases in Psoriasis. Clinical Cases in Dermatology. Springer, Cham. https://doi.org/10.1007/978-3-030-18772-9_15
Download citation
DOI: https://doi.org/10.1007/978-3-030-18772-9_15
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-18771-2
Online ISBN: 978-3-030-18772-9
eBook Packages: MedicineMedicine (R0)